Serial Liver Stiffness Measurement and Serum Biomarkers Are Not Strong Predictors of the Regression of Fibrosis among Chronic Hepatitis B Patients Receiving Antiviral Therapy Based on Triple Liver Biopsies
Changes in the LSM and noninvasive models were not strong predictors of liver fibrosis regression after 78 weeks and 260 weeks of treatment among CHB patients. It is critical to develop a dynamic noninvasive model for assessing liver fibrosis regression (ClinicalTrials.gov identifier NCT02849132).
Authors
- Yameng Sun (ORCID: https://orcid.org/0000-0003-2981-9936)
- Yuanyuan Kong (ORCID: https://orcid.org/0000-0002-2586-1443)
- Xinyu Zhao (ORCID: https://orcid.org/0000-0003-4123-3030)
- Jialing Zhou (ORCID: https://orcid.org/0000-0001-5075-6656)
- Hong You (ORCID: https://orcid.org/0000-0001-9409-1158)
- Shuyan Chen (ORCID: https://orcid.org/0000-0003-2400-8413)
- Xiaoqian Xu (ORCID: https://orcid.org/0000-0001-9269-2283)
- Jiayi Zhang (ORCID: https://orcid.org/0009-0002-2907-2692)
- Xiaoning Wu (ORCID: https://orcid.org/0000-0001-5416-712X)
- Bingqiong Wang (ORCID: https://orcid.org/0009-0005-3439-6810)
- Xiaojuan Ou (ORCID: https://orcid.org/0009-0002-4662-4970)
Institutions
- Capital Medical University (CN)
- National Clinical Research Center for Digestive Diseases (CN)
- Beijing Friendship Hospital (CN)
Publication Details
- Journal
- Gut and Liver
- Published
- 2025-11-14
- DOI
- https://doi.org/10.5009/gnl250008
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00